FY2017 EPS Estimates for Illumina Inc. Lowered by Cantor Fitzgerald (ILMN)
Illumina Inc. (NASDAQ:ILMN) – Equities research analysts at Cantor Fitzgerald lowered their FY2017 EPS estimates for Illumina in a research note issued to investors on Wednesday. Cantor Fitzgerald analyst B. Brokmeier now forecasts that the firm will post earnings per share of $4.00 for the year, down from their previous forecast of $4.20. Cantor Fitzgerald has a “Hold” rating and a $155.00 price objective on the stock.
A number of other equities research analysts have also recently issued reports on the stock. Morgan Stanley cut shares of Illumina from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $130.00 to $110.00 in a research note on Tuesday, July 5th. Vetr upgraded Illumina from a “sell” rating to a “buy” rating and set a $198.61 price objective on the stock in a report on Monday, October 3rd. CL King lowered Illumina from a “buy” rating to a “neutral” rating in a report on Monday, August 22nd. JPMorgan Chase & Co. lifted their price target on Illumina from $185.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 27th. Finally, Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Illumina currently has an average rating of “Hold” and a consensus target price of $157.50.
Illumina (NASDAQ:ILMN) traded up 0.73% on Thursday, reaching $137.17. 2,105,322 shares of the company’s stock were exchanged. The firm has a market cap of $20.11 billion, a PE ratio of 46.98 and a beta of 0.47. Illumina has a one year low of $127.10 and a one year high of $196.47. The firm has a 50 day moving average price of $172.97 and a 200 day moving average price of $156.29.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/fy2017-eps-estimates-for-illumina-inc-lowered-by-cantor-fitzgerald-ilmn.html
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business had revenue of $600 million for the quarter, compared to analysts’ expectations of $31.91 million. During the same quarter in the previous year, the business posted $0.80 earnings per share. The business’s revenue was up 11.3% compared to the same quarter last year.
In other news, Director Robert S. Epstein sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $150.00, for a total transaction of $180,000.00. Following the completion of the sale, the director now owns 7,824 shares in the company, valued at $1,173,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roy A. Whitfield sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, August 12th. The stock was sold at an average price of $167.22, for a total value of $668,880.00. Following the sale, the director now owns 6,853 shares of the company’s stock, valued at approximately $1,145,958.66. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in ILMN. Checchi Capital Advisers LLC raised its position in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares in the last quarter. Cleararc Capital Inc. raised its position in shares of Illumina by 0.7% in the first quarter. Cleararc Capital Inc. now owns 3,344 shares of the life sciences company’s stock worth $542,000 after buying an additional 23 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its position in shares of Illumina by 1.1% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 3,698 shares of the life sciences company’s stock worth $467,000 after buying an additional 39 shares in the last quarter. Nippon Life Insurance Co. raised its position in shares of Illumina by 0.5% in the second quarter. Nippon Life Insurance Co. now owns 7,877 shares of the life sciences company’s stock worth $1,106,000 after buying an additional 40 shares in the last quarter. Finally, Regent Investment Management LLC raised its position in shares of Illumina by 1.8% in the second quarter. Regent Investment Management LLC now owns 4,250 shares of the life sciences company’s stock worth $597,000 after buying an additional 75 shares in the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.